Kyverna Therapeutics (KYTX) Change in Accured Expenses (2023 - 2026)

Kyverna Therapeutics (KYTX) has 4 years of Change in Accured Expenses data on file, last reported at -$6.9 million in Q1 2026.

• Quarterly Change in Accured Expenses fell 281.15% year-over-year to -$6.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $35000.0 (down 97.96% YoY) and the FY2025 annual result came in at $5.1 million, up 146.6% from the prior year.
• Change in Accured Expenses slipped to -$6.9 million in Q1 2026, from $3.0 million in the prior quarter.
• In the past five years, Change in Accured Expenses ranged from a high of $3.0 million in Q4 2025 to a low of -$6.9 million in Q1 2026.
• A 4-year average of $131000.0 and a median of $719000.0 in 2023 frame the typical range for Change in Accured Expenses.
• Annual changes were most pronounced in 2025 — Change in Accured Expenses surged 583.97% — and 2026, when it tumbled 281.15%.
• Tracing KYTX's Change in Accured Expenses over 4 years: stood at $957000.0 in 2023, then plunged by 53.71% to $443000.0 in 2024, then surged by 583.97% to $3.0 million in 2025, then tumbled by 326.93% to -$6.9 million in 2026.
• The last three Change in Accured Expenses figures came in at -$6.9 million (Q1 2026), $3.0 million (Q4 2025), and $2.0 million (Q3 2025), per Business Quant data.